MUC1, however, was found to be a potential anti-neoplastic antigen because of its change in the expression profile of normal and cancer cells, and it has been identified by the American Cancer Institute Working as one of the most promising cancer vaccine-targeted antigens in clinical trials [21]. The gene discussed is MUC1; the disease is cancer.